• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cel-Sci raises $3.5m for head and neck cancer immunotherapy

August 23, 2017 By Sarah Faulkner

cel-sciCel-Sci (NYSE:CVM) said today that it inked an agreement with institutional investors for a $3.5 million registered direct offering.

The company said it plans to offer 1.75 million shares of common stock at $2.00 apiece. In a private placement, Cel-Sci will issue warrants to buy up to 1.75 million shares of common stock. For each share of stock purchased in the registered direct offering, investors in the private placement will receive an unregistered warrant to buy one share of common stock, which have an exercise price of $2.30 apiece.

The company is slated to use the offering’s net proceeds for a Phase III trial of its investigational immunotherapy, Multikine.

Earlier this month, the FDA lifted a partial hold on Cel-Sci’s late-stage Multikine trial. The hold was put in place in September last year, with the regulatory watchdog citing issues like an unreasonable and significant risk of illness or injury to participants and the lack of prompt reports by Cel-Sci to the FDA on particular issues.

The FDA also claimed that the Vienna, Va.-based company’s investigator brochure was misleading and materially incomplete, according to the Washington Business Journal.

Cel-Sci’s Multikine leukocyte interleukin injection is being evaluated as a potential therapy for patients with squamos cell carinoma of the head and neck.

The Phase III trial’s primary endpoint is an improvement in overall survival of the participants treated with the Multikine therapy plus the current standard of care compared to people treated with just the current standard of care.

CVM shares tumbled down to $1.95 apiece in morning activity today, a -15% drop.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Clinical Trials, Featured, Funding Roundup, Immunotherapy, Oncology, Wall Street Beat Tagged With: cel-sci

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS